display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - adjuvantbreast cancer - HER2-positivebreast cancer - HR positive
breast cancer - adjuvantes-BC - HER2 positive - (neo)adjuvant (NA)la/mBC - HER2 positive - 1st Line (L1)la/mBC - HER2 positive - 2nd Line (L2)la/mBC - HR-positive - 1st line (L1)
HER inhibitor
EGFR inhibitor
afatinib based treatment
afatinib plus vinorelbine LUX-Breast 1
HER2 inhibitor
neratinib based treatment
neratinib ExteNET ExteNET
neratinib plus capecitabine NALA NALA ...
pertuzumab based treatment
pertuzumab plus trastuzumab APHINITY IMpassion-050 IMpassion-050 IMpassion-050 PERTAIN
pertuzumab plus trastuzumab plus docetaxel PUFFIN CLEOPATRA
trastuzumab based treatment
docetaxel plus carboplatin with trastuzumab followed by trastuzumab BCIRG-006 ...
doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab BCIRG-006 ... BCIRG-006 ...
trastuzumab plus endocrine therapy SYSUCC-002 SYSUCC-002
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel GeparQuinto
tucatinib based treatment
tucatinib plus trastuzumab plus capecitabine HER2CLIMB HER2CLIMB ...
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib plus capecitabine WJOG6110B/ELTOP
lapatinib plus fulvestrant CALGB 40302
lapatinib plus letrozole EGF30008 ... EGF30008 ...
lapatinib plus trastuzumab EGF104900

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons